Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRSP vs EDIT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CRSP Captures Overall Composite Edge (48.6 HOLD vs 51.6 HOLD), While EDIT Leads 4–2 on Growth & Valuation Pillars
CRSP Overall Winner
6-Pillar Tally: CRSP 2 – 4 EDIT
Matrix Metrics: CRSP 7 – 3 EDIT
As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (48.6/100 HOLD vs. 51.6/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Growth & Scale), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. CRSP trades at $40.61 (23.4x Forward P/E, -2058.6% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin).
- Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -167.0% operating margin) and revenue trajectory (+1325.1% vs. +37.4% YoY).
- Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CRSP vs EDIT
CRSP
Head-to-Head Winner
CRISPR Therapeutics AG
$40.61
-3.86% 1D
Market Cap
$4.1B
TTM Revenue
$25M
Forward P/E
23.4x
Beta / 30D Vol
1.85β · 60% Vol
Unified Composite Score
48.6
HOLD
Tech 33.0
Fund 51.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
EDIT
Editas Medicine, Inc. Common Stock
$1.91
-12.21% 1D
Market Cap
$336.5M
TTM Revenue
$50M
Forward P/E
N/M
Beta / 30D Vol
2.32β · 102% Vol
Unified Composite Score
51.6
HOLD
Tech 40.0
Fund 54.0
Flow 69.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CRSP 2 – 4 EDIT)
1. Valuation Multiples
CRSP
Forward P/E
23.4x
N/M
Trailing P/E
23.4x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
5.2x
2. Growth & Scale
CRSP
Revenue Growth (YoY)
+1325.1%
+37.4%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$25M
$50M
Market Cap
$4.1B
$336.5M
3. Profitability & Quality
EDIT
Gross Margin
N/A
-73.3%
Operating Margin
-2058.6%
-167.0%
Net Profit Margin
0.0%
-144.9%
Return on Equity (ROE)
-25.6%
-147.4%
4. Balance Sheet & Cash Flow
EDIT
Cash Generation (TTM)
-$378M
-$110M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$588M Net Debt (0.47x D/E)
$79M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EDIT
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
97.8% (52nd %ile)
95.8% (38th %ile)
Put/Call OI Skew
0.65x (Call-Skewed)
0.29x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
EDIT
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Concentrated Oligopoly Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CRSP (7) vs EDIT (3)| Institutional Metric | CRSP | EDIT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $4.1B | $336.5M | CRSP | |
| Trailing P/E Ratio | 23.4x | N/M | CRSP | |
| Forward P/E Ratio | 23.4x | N/M | CRSP | |
| Revenue Growth (YoY) | +1325.1% | +37.4% | CRSP | |
| Operating Margin (TTM) | -2058.6% | -167.0% | EDIT | |
| Net Profit Margin | 0.0% | -144.9% | CRSP | |
| Return on Equity (ROE) | -25.6% | -147.4% | CRSP | |
| 52-Week Range Position | 1% ($40–$63) | 11% ($2–$4) | EDIT | |
| Beta / 30D Volatility | 1.85β · 60% Vol | 2.32β · 102% Vol | CRSP | |
| Unified Institutional Score | 48.6 / 100 (HOLD) | 51.6 / 100 (HOLD) | EDIT | |
| Trailing 12M Revenue (USD) | $25M | $50M | Scale | |
| Gross Profit Margin (TTM) | N/A | -73.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 5.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$378M ($588M Net Debt (0.47x D/E)) | -$110M ($79M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CRSP +1.4 pp
3M Horizon
CRSP +10.52 pp
6M Horizon
CRSP +8.33 pp
1Y Horizon
CRSP +4.46 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRSP Revenue | EDIT Revenue | CRSP Op. Margin | EDIT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $30M | -5087.8% | -356.1% | EDIT |
| FY2019 | $290M | $20M | 16.1% | -686.4% | CRSP |
| FY2020 | $0M | $90M | -49295.5% | -148.6% | EDIT |
| FY2021 | $910M | $30M | 40.8% | -756.1% | CRSP |
| FY2022 | $0M | $20M | -56190.4% | -1146.3% | EDIT |
| FY2023 | $370M | $80M | -60.0% | -216.6% | CRSP |
| FY2024 | $40M | $30M | -1250.4% | -777.2% | EDIT |
| FY2025 | $0M | $40M | -18933.6% | -394.9% | EDIT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CRSP
BREAKDOWN
Current IV
97.8%
IV Percentile
52nd %ile
Put/Call OI Skew
0.65x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EDIT
BREAKDOWN
Current IV
95.8%
IV Percentile
38th %ile
Put/Call OI Skew
0.29x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CRSP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EDIT Moat Profile
Concentrated Oligopoly Moat
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published · CRISPR / Gene Editing
Investor FAQ CRSP vs EDIT Key Questions & Quantitative Answers
As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (48.6/100 HOLD vs. 51.6/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Growth & Scale), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. CRSP trades at $40.61 (23.4x Forward P/E, -2058.6% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -167.0% operating margin) and revenue trajectory (+1325.1% vs. +37.4% YoY). Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRSP leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while EDIT shifted +33.3%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.
CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus EDIT (-147.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EDIT vs CRSP · Reverse Pair
CRSP vs NTLA
· Sector Peer
CRSP vs TDOC
· Sector Peer
CRSP vs BEAM
· Sector Peer
EDIT vs NTLA
· Sector Peer
EDIT vs BEAM
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem